ATLANTA, GA – – (Globe Newswire – August 1, 2023) – – Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). The lawsuit alleges Aldeyra made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and compliance policies, including: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; and (iii) accordingly, the Company had overstated ADX-2191’s clinical and/or commercial prospects.
If you bought shares of Aldeyra between March 17, 2022 and June 20, 2023, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/aldeyra/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is September 29, 2023.
Lead Plaintiff Deadline Has Passed
September 29, 2023